Indications
Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
Composition
- Active substance
- dimethyl fumarate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Skilarence
- Active substance
- dimethyl fumarate
- ATC code
- L04AX07
- Therapeutic area
- Psoriasis
- Marketing authorisation holder
- Almirall, S.A.
- Status
- Authorised
- EU authorisation
- 23 Jun 2017